---

Risk Factors:

Contraindications: Hypersensitivity to tiZANidine. Concurrent use with strong CYP1A2 inhibitors.Pregnancy: Risk cannot be ruled out. Lactation: Caution advised or effect undetermined. Contraindications: Severe hepatic impairment. Precautions: Impaired liver or kidney function. Perform LFTs monthly for 1st four months: discontinue if enzymes persistently >3 x ULN. Cardiovascular disorders coronary artery disease. Elderly.

---

Indications:

Acute and intermittent management of muscle spasticity (spasms stiffness rigidity) spasticity associated with multiple sclerosis or spinal cord Injectionury.

---

Adverse Effects:

Frequent (49%?41%): Dry mouth drowsiness asthenia. Occasional (16%?
4%): Dizziness UTI constipation. Rare (3%): Nervousness amblyopia
pharyngitis rhinitis vomiting urinary frequency.
Adverse effects/toxic reactions
Hypotension may be associated with bradycardia orthostatic hypotension and
rarely syncope. Risk of hypotension increases as dosage increases; hypotension
is noted within 1 hr after administration. May cause visual hallucinations.

---

Don’t Use:

Cautions: Renal/hepatic disease pts at risk for severe
hypotensive effects cardiac disease psychiatric disorders elderly pts.